Aptargroup Stock Price, News & Analysis

AptarGroup (NYSE: ATR), a leader in drug and consumer product dosing and dispensing technologies, has released its 2024 Corporate Sustainability Report. The report showcases progress across three key pillars: Care, Collaboration, and Circularity. Key achievements include: • 97.5% of electricity sourced from renewables • 86% of operational waste avoided landfill disposal • 60% of sites earned Landfill Free Certification The company partnered with organizations like Ellen MacArthur Foundation and World Business Council for Sustainable Development to advance circular solutions. Aptar's sustainability initiatives focus on increasing recycled resin content and developing recyclable, reusable, or compostable solutions across their product lines. The report, prepared under GRI Standards, received external assurance for its emissions reporting from SGS do Brasil Ltda.

AptarGroup (NYSE:ATR) reported Q1 2025 results with reported sales of $887 million, down 3% year-over-year, and net income of $79 million, a 5% decrease. Core sales remained flat while adjusted EBITDA increased 3% to $183 million. The company achieved an adjusted EBITDA margin of 20.7%, expanding 120 basis points. Adjusted EPS was $1.20, which would have shown a 5% increase excluding currency effects and tax rate changes. Notably, Pharma segment showed strength with 2% growth in proprietary drug delivery systems sales. The company returned $110 million to shareholders, including $80 million in share repurchases. By segment, Aptar Pharma's core sales grew 3%, while Beauty and Closures segments declined 3% and 2% respectively. Looking ahead, Aptar expects Q2 2025 adjusted EPS of $1.56-$1.64.

AptarGroup (NYSE: ATR), a leader in drug and consumer product dosing, dispensing and protection technologies, has announced a quarterly cash dividend of $0.45 per share. The dividend will be paid on May 22, 2025, to stockholders of record as of May 1, 2025.

The company has also scheduled a conference call on May 2, 2025 at 8:00 a.m. Central Time to discuss their first quarter 2025 results. The hour-long call will be available via live webcast on the Investors page at www.aptar.com, with a replay option accessible afterward.

AptarGroup (NYSE: ATR) has announced the launch of a clinical validation study for its SmartTrack™ platform, developed by its drug services company Nanopharm. The platform aims to reduce the need for clinical studies in generic drug product approvals by accurately predicting clinical outcomes for pressurized metered-dose inhalers (pMDI).

The study, scheduled to begin in Q2 2025, will involve radio-labelling three different commercial pMDI drug products and imaging regional lung deposition. The results will be compared with computational fluid dynamic simulations in collaboration with Fluidda, Medimprove, and i2c Pharmaceutical Services.

Upon completion by the end of 2025, the study data will be submitted to the U.S. FDA as one of the first Model Master Files (MMF). If validated, SmartTrack™ could accelerate approvals for generic inhaled medicines and support various programs, including pMDI reformulation with lower global warming potential propellants.

AptarGroup (NYSE: ATR), a leader in drug and consumer product dosing and dispensing technologies, has achieved the EcoVadis Platinum rating for the fifth consecutive year, placing it in the top 1% of over 150,000 rated companies across all industries.

The EcoVadis assessment evaluates performance across environment, labor and human rights, ethics, and sustainable procurement. Aptar utilizes EcoVadis for its Supplier Screening Program to integrate social and environmental screenings into purchasing processes.

The company's sustainability initiatives include eco-efficient operations, renewable energy adoption, and sustainable product development. Aptar is a member of the UN Global Compact, Ellen MacArthur Foundation, and World Business Council for Sustainable Development. The company has also received an 'A' score on CDP Climate Change assessment and was named among Barron's 100 Most Sustainable U.S. Companies.

AptarGroup (NYSE: ATR) has achieved a significant milestone by being ranked #26 on Barron's 100 Most Sustainable U.S. Companies for 2025, marking their seventh consecutive year on this prestigious list.

The company's sustainability achievements include:

• Maintaining EcoVadis Platinum rating since 2021, placing them in the top 1% of 150,000 rated companies
• Sourcing over 95% of global electricity from renewable sources
• Certifying more than 60% of sites as Landfill Free
• Setting science-based targets for emissions reduction aligned with 1.5°C warming limit by 2030
• Earning a spot on CDP's 'A List' for climate change leadership through 2024

The ranking was developed through Barron's partnership with Calvert Research and Management, evaluating the 1,000 largest publicly traded companies across 230 performance indicators.

AptarGroup (NYSE: ATR), a leader in drug and consumer product technologies, has achieved the prestigious 'A List' ranking on CDP's Climate Change Assessment for 2024. The recognition comes from the company's demonstrated efforts in emission reduction, climate risk mitigation, and advancement of the low-carbon economy.

Among 24,800 responding companies, Aptar stood out for its environmental initiatives, including:

• Setting science-based targets for Scope 1 and 2 emissions reductions aligned with 1.5°C warming limit by 2030
• Implementing renewable electricity targets and Scope 3 goals validated by Science Based Targets Initiative
• Securing Power Purchase Agreements in Europe and US for localized renewable energy
• Obtaining ISO 14046 certification for greenhouse gas emissions reduction

The CDP assessment, which evaluated data from companies representing over 142 trillion USD in assets, uses a comprehensive scoring system from A to D- based on environmental disclosure, risk management, and leadership practices.

AptarGroup (NYSE:ATR) reported strong Q4 2024 results with a 1% increase in reported sales to $848 million and a 62% increase in net income to $101 million. Core sales grew 2% despite negative currency effects. The company's pharma franchise achieved 8% sales growth for the full year 2024, while net income grew 32% to $375 million.

Q4 segment performance showed Aptar Pharma's core sales up 4%, Aptar Beauty's core sales down 3%, and Aptar Closures' core sales up 7%. The company reported Q4 earnings per share of $1.49, a 60% increase year-over-year. Full-year 2024 reported sales increased 3% to $3.58 billion, with adjusted earnings per share of $5.64, up 18% from the previous year.

For Q1 2025, Aptar expects earnings per share between $1.11 and $1.19, facing headwinds from foreign currencies and higher tax rates. The company also announced a $500 million share repurchase authorization and a quarterly dividend of $0.45 per share.

AptarGroup (NYSE: ATR) has announced its Board's declaration of a quarterly cash dividend of $0.45 per share, payable on February 26, 2025, to stockholders of record as of February 5, 2025. The company will host a conference call on February 7, 2025, at 8:00 a.m. Central Time to discuss Q4 and full-year 2024 results.

Additionally, Aptar has scheduled its 2025 Annual Meeting of Stockholders to be held virtually on May 7, 2025, at 9:00 a.m. Central Time. Shareholders of record as of March 14, 2025, will be eligible to vote at the meeting.